Benitec Biopharma Inc. Stock-Based Compensation
Benitec Biopharma Inc. (BNTC) reported Stock-Based Compensation of $26.41 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-09-14
- Benitec Biopharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $6.26M, a 2.46% increase year-over-year.
- Benitec Biopharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $7.59M, a 1.96% decline year-over-year.
- Benitec Biopharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $7.38M, a 135.15% increase year-over-year.
- Benitec Biopharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $5.18M, a 1090.80% increase year-over-year.
- Benitec Biopharma Inc. share-based payment arrangement, noncash expense for fiscal 2026 was $26.41M, a 51.56% increase from fiscal 2025.
- Benitec Biopharma Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $17.43M, a 1999.52% increase from fiscal 2024.
- Benitec Biopharma Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $830.00K, a 83.63% increase from fiscal 2023.
- Benitec Biopharma Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $452.00K, a 48.05% decline from fiscal 2022.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-14 | $13.85M derived: sum of 2 quarters · filed 2026-09-14 | $21.23M derived: sum of 3 quarters · filed 2026-09-14 | $26.41M 10-K · filed 2026-09-14 | ||
| 2026-03-31 | $7.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-14 | $14.97M derived: sum of 2 quarters · filed 2026-05-14 | $20.15M 10-Q · filed 2026-05-14 | $26.26M derived: sum of 4 quarters · filed 2026-09-14 | ||
| 2025-12-31 | $7.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $12.56M 10-Q · filed 2026-02-12 | $18.67M derived: sum of 3 quarters · filed 2026-09-14 | $26.41M derived: sum of 4 quarters · filed 2026-09-14 | ||
| 2025-09-30 | $5.18M 10-Q · filed 2025-11-14 | $11.29M derived: sum of 2 quarters · filed 2026-09-14 | $19.03M derived: sum of 3 quarters · filed 2026-09-14 | $22.17M derived: sum of 4 quarters · filed 2026-09-14 | ||
| 2025-06-30 | $6.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-14 | $13.85M derived: sum of 2 quarters · filed 2026-09-14 | $16.99M derived: sum of 3 quarters · filed 2026-09-14 | $17.43M 10-K · filed 2026-09-14 | ||
| 2025-03-31 | $7.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-14 | $10.88M derived: sum of 2 quarters · filed 2026-05-14 | $11.32M 10-Q · filed 2026-05-14 | $3.98M 10-Q · filed 2025-05-14 | $11.77M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $3.57M 10-Q · filed 2026-02-12 | $1.38M 10-Q · filed 2025-02-14 | $4.03M derived: sum of 3 quarters · filed 2026-03-20 | $4.22M derived: sum of 4 quarters · filed 2026-03-20 | |
| 2024-09-30 | $435.00K 10-Q · filed 2025-11-14 | $889.00K derived: sum of 2 quarters · filed 2026-03-20 | $1.08M derived: sum of 3 quarters · filed 2026-03-20 | $1.17M derived: sum of 4 quarters · filed 2026-03-20 | ||
| 2024-06-30 | $454.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-20 | $646.00K derived: sum of 2 quarters · filed 2026-03-20 | $739.00K derived: sum of 3 quarters · filed 2026-03-20 | $830.00K 10-K/A · filed 2026-03-20 | ||
| 2024-03-31 | $192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | $285.00K derived: sum of 2 quarters · filed 2025-05-14 | $376.00K 10-Q · filed 2025-05-14 | $503.00K derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | $184.00K 10-Q · filed 2025-02-14 | $311.00K derived: sum of 3 quarters · filed 2025-02-14 | $382.00K derived: sum of 4 quarters · filed 2025-02-14 | ||
| 2023-09-30 | $91.00K 10-Q · filed 2024-11-14 | $218.00K derived: sum of 2 quarters · filed 2024-11-14 | $289.00K derived: sum of 3 quarters · filed 2024-11-14 | $241.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $198.00K derived: sum of 2 quarters · filed 2024-09-26 | $150.00K derived: sum of 3 quarters · filed 2024-09-26 | $452.00K 10-K · filed 2024-09-26 | ||
| 2023-03-31 | $71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-13 | $23.00K derived: sum of 2 quarters · filed 2024-05-13 | $325.00K 10-Q · filed 2024-05-13 | $493.00K derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | -$48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $254.00K 10-Q · filed 2024-02-13 | $422.00K derived: sum of 3 quarters · filed 2024-02-13 | $614.00K derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-09-30 | $302.00K 10-Q · filed 2023-11-13 | $470.00K derived: sum of 2 quarters · filed 2023-11-13 | $662.00K derived: sum of 3 quarters · filed 2023-11-13 | $901.00K derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-21 | $360.00K derived: sum of 2 quarters · filed 2023-09-21 | $599.00K derived: sum of 3 quarters · filed 2023-09-21 | $870.00K 10-K · filed 2023-09-21 | ||
| 2022-03-31 | $192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $431.00K derived: sum of 2 quarters · filed 2023-05-15 | $702.00K 10-Q · filed 2023-05-15 | $981.00K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $239.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-13 | $510.00K 10-Q · filed 2023-02-13 | $789.00K derived: sum of 3 quarters · filed 2023-02-13 | $1.02M derived: sum of 4 quarters · filed 2023-02-13 | ||
| 2021-09-30 | $271.00K 10-Q · filed 2022-11-10 | $550.00K derived: sum of 2 quarters · filed 2022-11-10 | $785.00K derived: sum of 3 quarters · filed 2022-11-10 | $867.00K derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-02 | $514.00K derived: sum of 2 quarters · filed 2022-09-02 | $596.00K derived: sum of 3 quarters · filed 2022-09-02 | $634.00K 10-K · filed 2022-09-02 | ||
| 2021-03-31 | $235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $317.00K derived: sum of 2 quarters · filed 2022-05-16 | $355.00K 10-Q · filed 2022-05-16 | $412.00K derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $82.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $120.00K 10-Q · filed 2022-02-14 | $177.00K derived: sum of 3 quarters · filed 2022-02-14 | $265.00K derived: sum of 4 quarters · filed 2022-02-14 | ||
| 2020-09-30 | $38.00K 10-Q · filed 2021-11-15 | $95.00K derived: sum of 2 quarters · filed 2021-11-15 | $183.00K derived: sum of 3 quarters · filed 2021-11-15 | $220.00K derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-20 | $145.00K derived: sum of 2 quarters · filed 2021-09-20 | $182.00K derived: sum of 3 quarters · filed 2021-09-20 | $237.00K 10-K · filed 2021-09-20 | ||
| 2020-03-31 | $88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-12 | $125.00K derived: sum of 2 quarters · filed 2021-05-12 | $180.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-09 | $92.00K 10-Q · filed 2021-02-09 | ||||
| 2019-09-30 | $55.00K 10-Q · filed 2020-11-13 | |||||
| 2019-06-30 | $672.00K 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |